Dr Tal Manor Kazam, MD in Altamonte Springs, FL - Medicare Ophthalmology

Dr Tal Manor Kazam, MD is a medicare enrolled "Ophthalmology" physician in Altamonte Springs, Florida. She graduated from medical school in 2005 and has 19 years of diverse experience with area of expertise as Ophthalmology. She is a member of the group practice Florida Eye Clinic P A and her current practice location is 160 Boston Ave # 32701, Altamonte Springs, Florida. You can reach out to her office (for appointments etc.) via phone at (407) 775-7654.

Dr Tal Manor Kazam is licensed to practice in Florida (license number ME154830) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1316142979.

Contact Information

	Dr Tal Manor Kazam, MD
	160 Boston Ave # 32701, Altamonte Springs, FL 32701-4798
	(407) 775-7654
	(407) 339-1203

Physician's Profile

Full Name	Dr Tal Manor Kazam
Gender	Female
Speciality	Ophthalmology
Experience	19 Years
Location	160 Boston Ave # 32701, Altamonte Springs, Florida
Accepts Medicare Assignments	Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Tal Manor Kazam graduated from medical school in 2005

NPI Data:

NPI Number: 1316142979
Provider Enumeration Date: 06/15/2007
Last Update Date: 10/20/2023

Medicare PECOS Information:

PECOS PAC ID: 7416093513
Enrollment ID: I20230920002705

Medical Identifiers

Medical identifiers for Dr Tal Manor Kazam such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1316142979	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207W00000X	Ophthalmology	241933 (New York)	Secondary
207W00000X	Ophthalmology	ME154830 (Florida)	Primary

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Florida Eye Clinic P A	6406758846	25

News Archive

Impax initiates challenge of patent listed by Shionogi Pharma concerning Fenoglide

Impax Laboratories, Inc. today confirms that it has initiated a challenge of a patent listed by Shionogi Pharma, Inc. in connection with its Fenoglide® (fenofibrate) tablets, 40 and 120 mg.

LDK378 compound well-tolerated in patients with ALK+ NSCLC

A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib-the only approved ALK inhibitor. Results of this Novartis-sponsored sudy will be presented by a researcher from Fox Chase Cancer Center during the 2012 Annual Meeting of the American Society of Clinical Oncology on Sunday, June 3.

Zogenix closes its $35M second tranche of Series B preferred stock financing

Zogenix, Inc., a privately held pharmaceutical company, announced today that it has closed a $35 million second tranche of a Series B preferred stock financing. The Series B round was increased from $51 million, previously announced in September, to $71 million. The additional $20 million investment was made by Chicago Growth Partners, which will now be represented on the Zogenix Board of Directors by Dr. Arda Minocherhomjee.

CMO to manufacture Gaia BioPharma's GAI-122 Mitochondria-targeted neuroprotective agent

AlphaRx Inc. announced today that its licensee, Gaia BioPharma Limited, has signed an agreement with a contract manufacturing organization (CMO), to manufacture GAI-122 for use in the planned Phase I and II clinical trials of that product candidate. GAI-122 is being developed as I.V. administered formulation of an intracellular neuroprotectant that employs AlphaRx's proprietary nano-emulsion formulation technology.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Tal Manor Kazam allows following entities to bill medicare on her behalf.

Entity Name	Florida Eye Clinic P A
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1417921180 PECOS PAC ID: 6406758846 Enrollment ID: O20040126000005

News Archive

Impax initiates challenge of patent listed by Shionogi Pharma concerning Fenoglide

Impax Laboratories, Inc. today confirms that it has initiated a challenge of a patent listed by Shionogi Pharma, Inc. in connection with its Fenoglide® (fenofibrate) tablets, 40 and 120 mg.

LDK378 compound well-tolerated in patients with ALK+ NSCLC

Zogenix closes its $35M second tranche of Series B preferred stock financing

CMO to manufacture Gaia BioPharma's GAI-122 Mitochondria-targeted neuroprotective agent

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Tal Manor Kazam is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Tal Manor Kazam, MD 1090 Amsterdam Ave, Suite 9a, New York, NY 10025-1737 Ph: (212) 662-0399	Dr Tal Manor Kazam, MD 160 Boston Ave # 32701, Altamonte Springs, FL 32701-4798 Ph: (407) 775-7654

News Archive

Impax initiates challenge of patent listed by Shionogi Pharma concerning Fenoglide

Impax Laboratories, Inc. today confirms that it has initiated a challenge of a patent listed by Shionogi Pharma, Inc. in connection with its Fenoglide® (fenofibrate) tablets, 40 and 120 mg.

LDK378 compound well-tolerated in patients with ALK+ NSCLC

Zogenix closes its $35M second tranche of Series B preferred stock financing

CMO to manufacture Gaia BioPharma's GAI-122 Mitochondria-targeted neuroprotective agent

Ophthalmology Doctors in Altamonte Springs, FL

Dr. Bradley Leone Shoss, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 160 Boston Ave, Altamonte Springs, FL 32701 Phone: 407-339-0303 Fax: 407-339-0961
Dr. Miguel Lugo, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 661 E Altamonte Dr, Suite 223, Altamonte Springs, FL 32701 Phone: 407-260-2255 Fax: 407-260-2831
Dr. Jose J Echegaray, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 616 E Altamonte Dr Ste 101, Altamonte Springs, FL 32701 Phone: 407-637-2096 Fax: 407-637-2097
Harry R Pappas, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 160 Boston Ave, Altamonte Springs, FL 32701 Phone: 407-834-7776 Fax: 407-834-0973
Thomas O Steedle, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 160 Boston Ave, Altamonte Springs, FL 32701 Phone: 407-834-7776 Fax: 407-834-0973
Osama Hassan Omar, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 220 N Westmonte Dr Ste F, Altamonte Springs, FL 32714 Phone: 407-389-0800 Fax: 407-389-1880

Dr Tal Manor Kazam, MD - Medicare Ophthalmology in Altamonte Springs, FL

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Group Practice Association

Impax initiates challenge of patent listed by Shionogi Pharma concerning Fenoglide

LDK378 compound well-tolerated in patients with ALK+ NSCLC

Zogenix closes its $35M second tranche of Series B preferred stock financing

CMO to manufacture Gaia BioPharma's GAI-122 Mitochondria-targeted neuroprotective agent

Medicare Reassignments

Impax initiates challenge of patent listed by Shionogi Pharma concerning Fenoglide

LDK378 compound well-tolerated in patients with ALK+ NSCLC

Zogenix closes its $35M second tranche of Series B preferred stock financing

CMO to manufacture Gaia BioPharma's GAI-122 Mitochondria-targeted neuroprotective agent

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Impax initiates challenge of patent listed by Shionogi Pharma concerning Fenoglide

LDK378 compound well-tolerated in patients with ALK+ NSCLC

Zogenix closes its $35M second tranche of Series B preferred stock financing

CMO to manufacture Gaia BioPharma's GAI-122 Mitochondria-targeted neuroprotective agent

Ophthalmology Doctors in Altamonte Springs, FL